ArticleFrontiers in oncology2026
Venous thromboembolism and secondary outcomes of bleeding and mortality in patients with gliomas: a multicenter cohort study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Venous thromboembolism (VTE) is a common and clinically significant complication in Central Nervous system (CNS) tumors, associated with increased hospitalization, morbidity, and mortality. This study estimates the cumulative incidence of VTE, bleeding, and all-cause mortality in patients with primary gliomas and evaluates their determinants using multivariable models accounting for competing risks, confounding, and missing data. Methods: This multicenter retrospective cohort study evaluated 334 adults with histologically confirmed primary gliomas treated across nine Brazilian centers (2021-2022; follow-up to December 2023). Outcomes included VTE, bleeding, and all-cause mortality. Sociodemographic, clinical, tumor-specific, treatment, and thromboprophylaxis data were collected. Twelve-month cumulative incidence was estimated using competing-risk methods. VTE and bleeding were assessed with Fine-Gray sub distribution hazard models, and mortality with Cox proportional hazards models. Results: VTE and bleeding cumulative incidences at 12 months were 11.8% (8.0 - 15.5% CI) and 4.7% (2.1 - 7.3% CI). The cumulative mortality incidence was 26.2%. Prior VTE (SHRadj = 4.28; 95% CI 2.60 - 7.07) and corticosteroid use (SHRadj = 3.25; 95% CI 2.20 - 4.81) independently increased VTE risk. Chronic kidney failure (SHRadj = 6.45; 95% CI 5.39 - 7.73) and diabetes mellitus SHRadj = 2.11; 95% CI: 1.51 - 2.95) were the independent predictor of bleeding. For mortality, gliomas NOS (HRadj = 9.20; 95% CI: 5.38-15.73) and GBM (HRadj = 10.34; 95% CI 4.28 - 24.96) were strongly associated with increased risk. Longer hospitalization (≥7 days; HRadj = 2.01; 95% CI 1.81 - 2.24), postoperative bleeding (HRadj = 2.92; 95% CI 2.10 - 4.13), and treatment in specialized cancer centers (HRadj = 2.59; 95% CI: 1.50 - 4.50), along with demographic characteristics, were also associated with higher mortality. Conclusion: In this multicenter Brazilian cohort of patients with primary gliomas, VTE was frequent, while bleeding was less common but clinically relevant. Mortality risk was driven by patient characteristics, tumor aggressiveness, and hospitalization factors, underscoring the need for individualized risk stratification. Within the subgroup analysis for mortality, higher educational level was associated with lower hazard of death, whereas prolonged hospitalization and postoperative bleeding consistently increased mortality risk across both GBM and grade 3 or 4 tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.